| Name | Title | Contact Details |
|---|
White Drive Products, also known as White Drive Motors and Steering, is a global manufacturer specializing in hydraulic motors, steering solutions, and hydraulic pumps. Founded in the early 1960s by Harvey White and his family, the company has transitioned from agricultural implements to become a recognized leader in the hydraulic industry. It is part of the Interpump Group and is committed to innovation, quality, and customer satisfaction. The company offers a wide range of products, including hydraulic motors designed for various applications, advanced steering units for mobile hydraulic systems, and durable hydraulic pumps. White Drive Products also provides technical support and comprehensive repair and maintenance services to ensure optimal performance of its products. With manufacturing facilities in the United States and Europe, along with a global distribution network, the company effectively serves customers in sectors such as agriculture, construction, and mining.
The Pipeline Group is a prominent provider of outsourced sales development solutions tailored for B2B technology companies. Founded in 2017 by Ken Jisser, the company is headquartered in San Jose, California, and has grown to employ between 300 and 410 people. It has been recognized as one of Americas fastest-growing private companies, ranking #415 by Inc. Magazine in 2020. The company operates on a bootstrapped model, generating revenue through private equity partnerships and customer referrals, with reported revenue of $63 million. The Pipeline Group offers an SDR-as-a-Service model, which includes dedicated remote sales teams for lead generation and pipeline acceleration. Their services are supported by proprietary technology that integrates data services and CRM tools, enhancing outreach efforts. They also provide temp-to-perm solutions to help clients manage SDR attrition and offer managed services such as content creation and campaign execution. The company emphasizes high-quality talent and guarantees outcomes based on activity volume and pipeline quality, supporting over 100 active partnerships with private equity firms and technology innovators.
Aegis Sortation is a technology and innovation leader specializing in the Freight and Parcel, Warehouse and Distribution, and E-Commerce industries. At Aegis we are innovating today to transform industries tomorrow! Innovation is the engine that drives our company forward and generates the creative forces behind everything we do and make. We are dedicated to providing exceptional service for our customers and exceeding industry standards for speed, durability, and safety. Our products are specifically designed to transform business; always, with no exceptions. This approach allows us to take advantage of both tried-and-true practices as well as applicable cutting-edge technologies. Aegis is determined to bring innovation, excellence and results to every project and partnership.
Hancock and Moore Fine Furniture
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.